Leveraging Outcomes Data - Operational Roles in Health Economics & Outcomes Research for CNS Products

Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Communications


Companies Profiled:
AbbVie; Alexion Pharmaceuticals; Bayer; Brii Biosciences; CSL Behring; Eisai; Greenwich Biosciences; Harmony Biosciences; Lundbeck; Merck; Novartis; Nucleus Global; Pfizer; Takeda Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged 16 executives from 14 pharmaceuticals offering CNS products. The study insights are mostly from directors and higher management executives, representing around ninety percent of the participants.

Key topics covered in this report include:

• HEOR involvement and its effectiveness in delivering value
• Health outcomes data usage and its effectiveness
• Role of HEOR in CNS health outcomes activities and data collection
• KPIs to measure success of HEOR
• Technology and tools used to demonstrate value
• Challenges and success factors in working with payers for CNS products

• Launch Investment:

• Early-stage lifecycle investments (<Phase III) build competitive advantage to maximize ROI and optimize commercial success.
• Mature commercial groups focus on early-stage HEOR investments to balance clinical and economic value propositions in drug development. Medical Affairs is slow to begin optimal launch investment.

• Training & KPIs: Expanding HEOR roles to support drug development and research collection require training on a quarterly and semi-annually basis. Effective HEOR programs measure impact via KPIs. 43% of respondents optimistic about tracking RWD in the future.

Sr. No.	Topic	Slide No.
I.	Executive Summary	p. 3-7
	Research Objectives & Methodology	p. 5
	Participating Companies & Titles	p. 6
	Segmentation Criteria	p. 7
II.	HEOR Structure, Collaboration and Involvement	p. 8-21
III.	Launch Investment for HEOR Activities	p. 22-23
IV.	Technology and Tools	p. 24-28
V.	Training and KPIs Measurement	p. 29-32
VI.	HEOR Staffing and Leadership	p. 33-36
VII.	Lessons Learned, Success Factors and Pitfalls	p. 37-40
VIII.	Participant Demographics	p. 41-43
IX.	Appendix	p. 44-49
X.	About Best Practices, LLC	p. 50

• Structure of CNS Health Economics and Outcomes Research (HEOR) group within the organization
• HEOR involvement vs. effectiveness for value delivery
• HEOR effectiveness at delivering value
• HEOR effectiveness at delivering value – Market Access vs. Medical Affairs
• Health outcomes data usage vs. effectiveness
• Utilization of listed types of health outcomes activities by the HEOR function
• Utilization of listed types of health outcomes activities by the HEOR function – Market Access vs. Medical Affairs
• Health outcomes activity effectiveness
• HEOR involvement level in each of the listed activities
• Sharing of medical information with various groups
• Organization’s role in health outcomes data collection
• Preferred frequency of communications (at a country & region level) with internal staff
• Roles played by HEOR team in carrying out activities designed to probe (payers) stakeholders’ needs and perspectives

• Point at which investment is started and point at which maximum investment is reached in the listed HEOR activities to develop value assessments for new CNS therapies

• Highly effective technologies for field communication
• Frequency of technology updates
• Annually updated technologies
• Tools used by HEOR group to demonstrate value/ communicate with payers

• Training and development programs that work best for HEOR groups
• Frequency of training provided to Health Outcomes groups
• Effective KPIs and metrics to measure the success of real world data program

• Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure
• Number of field staff that work in the HEOR organization and number of field-based staff dedicated to HEOR structure – Market Access vs. Medical Affairs
• Leadership level of the CNS HEOR group

• Top advantages to pursuing HEOR planning earlier in the R&D cycle
• Top success factors for HEOR in developing and maintaining strong capabilities for work with payer groups
• Topmost difficult challenges / pitfalls for HEOR in developing and maintaining strong capabilities for work with payer groups

• Geographic span of HEOR responsibility within participating companies
• Job titles of benchmark participants